Background-Patients with chronic heart failure (HF) frequently experience skeletal muscle weakness that limits physical function. The mechanisms underlying muscle weakness, however, have not been clearly defined. Methods and Results-This study examined the hypothesis that HF promotes a loss of myosin protein from single skeletal muscle fibers, which in turn reduces contractile performance. Ten patients with chronic HF and 10 controls were studied. Muscle atrophy was not evident in patients, and groups displayed similar physical activity levels, suggesting that observed differences reflect the effects of HF and not muscle atrophy or disuse. In single muscle fibers, patients with HF showed reduced myosin heavy chain protein content (PϽ0.05) that manifested as a reduction in functional myosin-actin cross-bridges (PϽ0.05). No evidence was found for a generalized loss of myofilament protein, suggesting a selective loss of myosin. Accordingly, single muscle fiber maximal Ca 2ϩ -activated tension was reduced in myosin heavy chain I fibers in patients (PϽ0.05). However, tension was maintained in myosin heavy chain IIA fibers in patients because a greater proportion of available myosin heads were bound to actin during Ca 2ϩ activation (PϽ0.01). Conclusions-Collectively, our results show that HF alters the quantity and functionality of the myosin molecule in skeletal muscle, leading to reduced tension in myosin heavy chain I fibers. Loss of single fiber myosin protein content represents a potential molecular mechanism underlying muscle weakness and exercise limitation in patients with HF. (Circ Heart Fail. 2009;2:700-706.)
P atients with chronic heart failure (HF) have a reduced capacity for physical work. Although cardiac dysfunction is the primary pathological insult, the resulting syndrome of HF alters numerous physiological systems to impair functional capacity. Alterations in skeletal muscle are of particular importance, most notably atrophy, 1 weakness, 2,3 and reduced endurance. 4 These peripheral skeletal muscle adaptations limit physical function independent of cardiac impairment 5 and persist despite correction of cardiac dysfunction. 6 
Clinical Perspective on p 706
Aerobic fitness is commonly assumed to be the primary determinant of physical function in patients with HF because exertional fatigue and dyspnea are predominant symptoms. However, aerobic capacity is a relatively poor predictor of performance in activities of daily living. 7 This is because most activities are limited instead by skeletal muscle strength. 8 Accordingly, functional capacity can be increased in patients with HF in the absence of alterations in aerobic capacity by improving muscle strength. 9 Despite its potential relevance to physical disability in patients with HF, few studies have explored the mechanisms underlying reduced skeletal muscle strength.
Skeletal muscle weakness in HF is not explained by muscle atrophy 2, 10 or reduced motor activation, 2 suggesting defects in the intrinsic contractile properties of individual muscle fibers. Recent studies in rats 11 and humans 12 in chemically skinned single muscle fibers have shown reduced contractile function in HF, implicating impaired myofilament protein function in muscle weakness. Because myosin is the most prevalent myofilament protein in muscle 13 and the primary determinant of single fiber contractile mechanics, 14 alterations in fiber function can be linked to variation in the quantity or function of the myosin molecule. In this context, our previous work demonstrating a reduction in myosin heavy chain (MHC) protein content in skeletal muscles of patients with HF 15 suggests that contractile dysfunction may result from a reduced quantity of myosin. Indeed, a recent study in rats with HF has shown reduced MHC protein content and force production in single diaphragm muscle fibers. 11 In addition, this study found alterations in myosin kinetic properties that could diminish contractile function. 11 However, whether similar alterations in the quantity and functionality of myosin occur in skeletal muscle of patients with HF has not been examined.
The aim of this study was to examine the effect of HF on single skeletal muscle fiber myofilament protein composition, function, and sarcomeric structure. To accomplish this objective, we evaluated single muscle fibers from the vastus lateralis muscle of patients with chronic HF and sedentary controls. Controls were recruited to match the low physical activity levels typically observed in patients with HF, 16 which obviates the effects of muscle activity level on single fiber structure and function. 17
Methods

Subjects
Ten patients (7 men and 3 women) with physician-diagnosed HF were recruited. The population consisted of patients with both systolic dysfunction (left ventricular ejection fraction Ͻ40%; nϭ6; 26.0Ϯ2.7%; range, 17% to 35%) and preserved systolic function (ejection fraction Ͼ40%; nϭ4; 46.8Ϯ1.8%; range, 45% to 52%). At the time of study, there were 1 New York Heart Association class I, 5 class II, and 4 class III patients. The etiology of HF was ischemic in 3 volunteers and nonischemic in 7. Three patients had type 2 diabetes mellitus. All patients were clinically stable and had not been hospitalized for at least 6 months before testing. None had evidence of hepatic, renal, or peripheral vascular disease or an active neoplastic process. Patients were receiving angiotensin-converting enzyme inhibitors/receptor blockers (100%), ␤-blockers (90%), diuretics (70%), and 3-hydroxy-3-methylglutaryl CoA reductase inhibitors (20%), and 1 female patient was receiving levothyroxine. Plasma creatine kinase levels were normal in all patients, and none were smokers or undergoing sex steroid replacement therapy.
Controls (nϭ10; 6 men and 4 women) recruited were sedentary or minimally active, as defined by self-report of Յ2 sessions of Ն30 minutes of exercise per week and not participating in any exercise training. Controls were nonsmokers; had a stable body weight (Ϯ2 kg during previous 6 months and not participating in a weight loss program); had no signs or symptoms of HF, coronary heart disease, or diabetes (fasting blood glucose Ͼ112 mg/dL); had normal left ventricular ejection fraction (Ͼ55%); had normal complete blood counts and routine biochemical values; and were not undergoing sex steroid replacement therapy. Four controls had a history of hypertension, and 3 were treated with diuretics and 1 with an angiotensin-converting enzyme inhibitor. All were normotensive at testing and showed no evidence of left ventricular hypertrophy or atrial enlargement by echocardiography. Two controls were on stable doses of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, and 1 woman was on levothyroxine. Plasma creatine kinase levels were normal in all controls. Informed consent was obtained from each volunteer, and the protocol was approved by the Committees on Human Research at the University of Vermont. Data showing reduced knee extensor muscle strength in patients with HF from this cohort have been published. 3
Experimental Protocol
Eligibility was determined during screening visits, at which time medical history, physical examination, blood samples, whole muscle strength testing, a treadmill test, and echocardiography were performed. At least 1 week later, eligible volunteers underwent an inpatient visit. Before admission, medications were maintained per normal dosing regimens, except coumadin (nϭ3), which was stopped 5 days before this visit. On the following morning, in the fasted state, body composition and midthigh muscle cross-sectional area were measured, and muscle tissue was obtained through percutaneous biopsy (Bergstrom needle, 5-mm outer diameter) of the vastus lateralis.
Total and Regional Body Composition
Total and regional fat mass and fat-free mass were measured by dual energy x-ray absorptiometry, as described previously. 15 Bone mass data are not reported. Midthigh muscle area was measured by computed tomography, as described previously. 18
Peak Oxygen Consumption
Peak oxygen consumption (peak VO 2 ) was determined using the Naughton protocol. 19
Accelerometry
Free-living physical activity was measured using a single-plane accelerometer, as described previously. 20
Muscle Tissue Processing
Approximately two thirds of the biopsy material was placed immediately into cold (4°C) dissecting solution (see online-only Data Supplement for composition of solutions). Remaining tissue was frozen in liquid nitrogen and stored at Ϫ80°C. Muscle fibers were dissected into bundles and tied to glass rods at 4°C and then placed in skinning solution for 24 hours at 4°C, storage solution with 50% (vol/vol) glycerol for 16 hours at 4°C, and finally stored at Ϫ20°C until study (within 4 weeks).
Tissue Homogenate MHC Protein Content and Isoform Distribution
Tissue MHC protein content and isoform distribution were determined on frozen muscle tissue, as described previously, 21 with minor modifications (see Data Supplement).
Single Muscle Fiber Morphology and MHC Protein Content
Segments (Ϸ3 mm) of single muscle fibers were measured in relaxing solution (20°C) to estimate fiber volume (see Data Supplement for details). Aliquots (1.5 m 3 fiber volume) of sample were analyzed for MHC and actin protein content in triplicate, according to previously published methods, 17, 22 with modifications (see Data Supplement). Thereafter, each fiber was analyzed for fiber type by means of MHC isoform expression (see Data Supplement).
Single Fiber Mechanical Measurements
Segments (Ϸ2.5 mm) of single fibers were isolated and their ends fixed with glutaraldehyde, as described elsewhere, 23 with modifications (see Data Supplement). Top and side diameter measurements were made in relaxing solution (pCa 8) at 3 positions to calculate cross-sectional area, and the fiber was incubated in dissecting solution containing 1% Triton X-100 (vol/vol) for 30 minutes. The fibers were attached to a piezoelectric motor and a strain gauge in relaxing solution, the sarcomere length was set to 2.65 m, and unfixed fiber length (Ϸ1 mm) was measured. All mechanical measurements were performed at 15°C. The fiber was transferred to preactivating solution for 30 seconds and then to activating solution (pCa 4.5), and tension was recorded at plateau. At plateau, sinusoidal length oscillations (10 cycles of 0.125% fiber length at 250 Hz) were imposed to measure fiber dynamic stiffness. Duplicate measurements of maximal Ca 2ϩ -activated tension and stiffness were obtained for each fiber. Thereafter, the fiber was placed in rigor solution, and at the plateau of tension, dynamic stiffness was measured. The amplitude of dynamic stiffness in the rigor state is proportional to the total number of available myosin heads that can bind actin (ie, total cross-bridge number), assuming all myosin heads bind to actin in rigor. The ratio of pCa 4.5 to rigor dynamic stiffness, therefore, provided an estimate of the fraction of available myosin heads that bind actin during Ca 2ϩ activation. After mechanical measurements, single fibers were analyzed for MHC isoform composition to identify fiber type.
Ultrastructural Measurements
Electron microscopy measurements were conducted on intact skeletal muscle fiber bundles, as described previously 24 (see Data Supplement for details).
Protein and Gene Expression
Immunoblotting techniques were used to assess MHC degradation products, according to the method of Ball et al, 25 and the quantity of ubiquitinated MHC (see Data Supplement). MHC isoforms, actin, muscle ring finger-1, and atrogin-1 mRNA levels were determined by real-time polymerase chain reaction (see Data Supplement).
Statistics
All data are reported as meanϮSE. Unpaired Student t tests were used to compare groups. Analysis of covariance was used to compare peak VO 2 data between groups after adjusting for differences in fat-free tissue mass.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Groups were similar for age, body size, body mass, and total and regional body composition. Peak VO 2 adjusted for fatfree mass was lower (PϽ0.01) in patients (Table 1) . Daily physical activity level measured by accelerometry over 7.6Ϯ0.4 days was similar between groups.
Patients with HF had lower MHC protein content in tissue homogenates compared with controls ( Figure 1A ; PϽ0.01), with no group differences in the relative distribution of MHC isoforms ( Figure 1B) .
Fibers from patients had greater average cross-sectional area compared with controls (PϽ0.01; Table 2 ) when all fibers were pooled, with or without inclusion of those fibers with MHC band densities less than or equal to background.
When partitioned into fiber types, patients had greater crosssectional area in MHC IIA and IIA/X fibers (PϽ0.01 for both) but not in MHC I fibers.
Patients with HF showed lower MHC protein content in single fibers whether or not fibers with MHC band densities less than or equal to background (nϭ39 fibers from patient group; nϭ25 fibers from control group) were included (PϽ0.01; Figure 2A ). Actin was detected in all fibers examined (see Data Supplement). In fibers with detectable MHC bands, patients with HF had lower MHC content in MHC I (PϽ0.05), MHC IIA (PϽ0.01), and MHC IIA/X (PϽ0.01) fibers ( Figure 2B ). There were too few MHC IIX and MHC I/IIA fibers to permit comparisons.
No group differences were evident for myofibrillar volume fraction, A-band length, or thick-to-thin filament ratio (Figure Data are meanϮSE. *Peak oxygen consumption data were adjusted for fat-free mass using analysis of covariance.
†PϽ0.01. Data are meanϮSE and reflect the average cross-sectional area from top and side diameter measurements every 250 m along the length of each fiber. Fibers with detectable MHC include only those with band densities greater than background, whereas all fibers includes those with band densities equal to or less than background. There were too few MHC IIX and I/IIA fibers to permit comparisons between groups. *PϽ0.01.
3 A through I). Average sarcomere length also did not differ (controls: 2.06Ϯ0.09 m versus patients with HF: 2.20Ϯ0.13 m), and no relationship between the sarcomere length and the thick-to-thin filament ratio was found (rϭ0.022; Pϭ0.94).
Single muscle fiber Ca 2ϩ -activated tension and dynamic stiffness data are shown in Figure 4 . Patients showed lower tension in MHC I fibers (PϽ0.05), whereas MHC IIA fibers remained similar to controls ( Figure 4A ). pCa 4.5 stiffness was decreased in MHC I fibers (PϽ0.01) and unchanged in MHC IIA fibers ( Figure 4B ), whereas rigor stiffness was decreased in both MHC I and MHC IIA fibers (both PϽ0.05; Figure 4C ) in patients. The pCa 4.5/rigor stiffness ratio did not differ between groups in MHC I fibers but was increased in MHC IIA fibers (PϽ0.01; Figure 4D ) in patients. Finally, there was a subset of fibers in controls (nϭ7) and patients (nϭ20) that failed catastrophically (ie, tore) on Ca 2ϩ activation.
No differences were found between patients (nϭ7) and controls (nϭ5) in mRNA abundance for MHC I (controls: 1.00Ϯ0.19 versus patients with HF: 1.10Ϯ0.33 relative expression), MHC IIA (controls: 1.00Ϯ0.14 versus patients with HF: 0.87Ϯ0.09), MHC IIX (controls: 1.00Ϯ0.37 versus patients with HF: 1.68Ϯ0.54), or actin (controls: 1.00Ϯ0.12 versus patients with HF: 0.96Ϯ0.10). Similarly, no group differences were noted for mRNA of any of these genes when data were analyzed using 18S RNA as the housekeeping gene (see Data Supplement). In addition, no differences between patients and controls in the amount of MHC I breakdown fragments ( Figure 5 
Discussion
In this study, we found reduced single fiber MHC protein content in patients with HF, which was manifested as a decreased number of functional myosin-actin cross-bridges. However, no evidence was found for a generalized loss of myofibrillar proteins, suggesting a selective loss of myosin. In keeping with reduced MHC protein/cross-bridge number, single fiber maximal Ca 2ϩ -activated tension (force per crosssectional area) was reduced in MHC I fibers from patients. Interestingly, tension was maintained in MHC IIA fibers from patients because a greater proportion of myosin heads bound actin during Ca 2ϩ activation, implying altered myosin kinetic properties. Our results represent the first demonstration of an effect of HF on the quantity and kinetic properties of the myosin molecule in single skeletal muscle fibers in humans.
Patients with HF are profoundly inactive relative to agematched, healthy controls, 16 which complicates group comparisons because inactivity modulates muscle structure and function. 26 To mitigate the effect of inactivity, we recruited sedentary controls to match patients for muscle use and confirmed that their activity levels were similar to patients. In addition, patients were tested Ն6 months after inpatient admissions to eliminate any acute effects of muscle disuse on single fiber structure or function. An interesting observation that highlights the importance of these experimental considerations is the similar MHC isoform distribution (ie, fiber type) in patients and controls ( Figure 1B) . Our fiber type results agree with studies that have similarly controlled the activity status of controls 9,27 but differ from those that have not. 15, 28, 29 In these latter studies, a shift in fiber type toward a fast-twitch phenotype was observed. 15, 28, 29 Because muscle disuse increases the proportion of fast-twitch fibers, 30 these results collectively suggest that one of the presumed hallmark muscle adaptations to HF-a switch to a fast-twitch phenotype-may simply be a repercussion of the muscle disuse imposed by the disease state. Thus, experimental control for physical activity patterns is necessary to identify alterations in myofilament protein content and function that are specific to HF.
At the single fiber level, MHC loss was evident in all fiber types examined from patients with HF ( Figure 2B) . These results extend evidence from rat models 11 to demonstrate, for the first time, that myosin is lost from single muscle fibers as a consequence of human HF. Further reinforcing our MHC content data, we found a decrease in single fiber dynamic stiffness in patients at the plateau of rigor tension (Figure 4C ), suggesting a loss of functional myosin heads that can bind actin to form cross-bridges. Because myosin comprises 25% of total skeletal muscle protein and 40% of myofilament protein, 13 this reduction may simply reflect a loss of myofilament protein secondary to muscle atrophy. However, the fact that we found no evidence for muscle atrophy in patients and no group differences in single fiber actin protein content (see Data Supplement) or myofibrillar volume fraction argues against this conclusion and implies a selective loss of myosin protein. This type of selective myosin depletion is not unique to HF and has been observed in acute quadriplegic myopathy patients 31 and a rat model of cancer, 32 suggesting that this phenotype may be common to a variety of acute and chronic disease states.
From a structural standpoint, loss of myosin could result from a decreased number of thick filaments, shortening of the thick filaments, and/or loss of myosin at random points along the thick filament. We found no evidence for a loss of thick filaments (thick-to-thin filament ratio) or shortening of the A-band (ie, thick filament) length in patients, implying a loss of myosin along the entire length of the thick filament. This structural phenotype of myosin depletion agrees with the fact that the thick filament is remodeled by replacing myosin at random points along the length of the filament. 33 Single fiber tension is directly related to the number of functional myosin heads, the proportion of these heads bound to actin during Ca 2ϩ activation, and the force generated per crossbridge. 34, 35 Thus, a loss of MHC protein would result in reduced single fiber tension. Correspondingly, tension was reduced in MHC I fibers from patients ( Figure 4A ). This reduction in tension is less than the decrement in MHC protein content/ cross-bridge number, which may be explained by the fact that the relationship between MHC protein content and tension seems to be nonlinear. 31 The nonlinear nature of this relationship may relate to alterations in cross-bridge kinetics, which accompany MHC protein depletion. 11 In addition, variance between single fiber MHC protein content and tension in our study may simply relate to the fact that measurements were preformed on 2 separate populations of fibers. Regardless of the underlying mechanisms, the diminution of function in MHC I fibers may be relevant to physical disability in patients with HF in light of the fact that MHC I fibers are recruited for repetitive movements typically encountered in daily activities. 36, 37 Moreover, diminished function in MHC I fibers may contribute to reduced exercise capacity because these fibers are important determinants of aerobic fitness in patients with HF. 38 In this context, loss of myosin protein represents a potential molecular mechanism underlying physical disability and exercise intolerance in HF.
Interestingly, despite the reduction in MHC content, no group differences in tension were found in MHC IIA fibers. The reason for this disparity was revealed when fiber stiffness was evaluated under maximal Ca 2ϩ -activated and rigor conditions, which demonstrated a greater proportion of myosin heads bound during Ca 2ϩ activation in MHC IIA fibers in patients ( Figure 4D ). As detailed above, a greater proportion of myosin heads bound to actin would increase tension. This adaptation could be explained by a change in myosin kinetic parameters, 11 which increases the amount of time myosin is bound to actin or decreases the amount of time myosin is detached from actin or both. Thus, our results suggest that HF alters both the quantity and the kinetic properties of the myosin molecule in skeletal muscle, with functional consequences that are fiber-type specific.
Our current results in single fibers differ from our previous findings in isolated myosin and thin filaments evaluated using the in vitro motility assay, which showed no effect of HF on force production or contractile velocity. 39 These differences between studies are likely due to differences in the 2 assays of myofilament function. In the in vitro motility assay, the quantity of myosin and thin filament proteins used is standardized, which negates the functional effect of MHC protein depletion evident in skinned fibers from patients with HF. Moreover, in the mixed fiber preparations used in the motility assay in our previous study, 39 myosin kinetic properties are dominated by MHC I molecules. 40 Hence, alterations in MHC IIA kinetics evident in skinned fibers ( Figure 4D ) would be masked in the motility assay. In addition, our results differ somewhat from previous studies that showed large reductions (Ͼ30%) in single fiber tension in MHC I and IIA fibers from patients with HF. 12 Here again, direct comparisons between studies are difficult because controls in this previous study were 12 years younger than patients and groups were not matched for physical activity level. Thus, the large tension reductions may have been related to aging and/or muscle disuse. 17 In contrast, patients and controls in our study were well matched for age and physical activity, making our findings more reflective of the direct effects of the HF syndrome.
In light of the potential relevance of MHC protein depletion, we sought to identify the mechanisms whereby HF promotes a loss of skeletal muscle myosin by measuring MHC mRNA abundance and indices of MHC protein degradation. No group differences in MHC mRNA abundance were found, suggesting no alteration in MHC gene transcription. These results differ from our previous work in which we observed a trend toward reduced MHC mRNA in patients. 10 This previous finding is likely explained by the fact that we did not match controls and patients for physical activity. Consequently, reduced MHC mRNA was explained entirely by decreased MHC I mRNA, 10 which is likely due to inactivity-induced reductions in MHC I gene expression. 30 This further emphasizes the importance of considering the activity status of controls. In addition, by using multiple techniques, we found no evidence for elevated MHC protein degradation in patients ( Figure 5 ). These results contrast with a recent work in a rat model of HF showing that pharmacological treatment with an inhibitor of protein breakdown can prevent the loss of MHC from single diaphragm fibers. 41 Reasons for differing results are not clear but may relate to the fact that we expect the HF syndrome to be more severe and rapidly progressive in this animal model compared with welltreated, clinically stable patients. These differences in disease status between animal models and patients highlight a potential explanation for the MHC protein content depletion observed in our study; specifically, that reduced MHC gene expression and increased proteolysis occur in patients and precipitate MHC protein loss during periods of acute disease exacerbation and hospitalization. These episodes are characterized by neurohumoral/immune activation 42, 43 and physical inactivity, both of which could contribute to the depletion of MHC protein. 17, 32 In conclusion, our results suggest selective myosin protein depletion from individual muscle fibers as a potential molecular mechanism contributing to skeletal muscle weakness in patients with HF. Because controls and patients were similar for age and physical activity level and there was no evidence for muscle atrophy in patients, we believe that this phenotype is reflective of the effects of the HF syndrome on skeletal muscle rather than the effects of aging, muscle atrophy, or physical inactivity. Moreover, the fact that these observations were made in well-treated patients with mild to moderate HF suggests that single muscle fiber myosin depletion is not merely a manifestation of end-stage disease but rather a distinct feature of the skeletal muscle myopathy of HF.
